Summary
50.00 -2.89(-5.45%)06/14/2024
Corbus Pharmaceuticals Holdings Inc (CRBP)
Corbus Pharmaceuticals Holdings Inc (CRBP)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-5.61 | 12.84 | 16.55 | 11.63 | 714.33 | 532.11 | -75.67 | -44.44 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 50.00 | |
Open | 52.33 | |
High | 52.50 | |
Low | 48.26 | |
Volume | 196,255 | |
Change | -2.97 | |
Change % | -5.61 | |
Avg Volume (20 Days) | 222,959 | |
Volume/Avg Volume (20 Days) Ratio | 0.88 | |
52 Week Range | 3.03 - 55.41 | |
Price vs 52 Week High | -9.76% | |
Price vs 52 Week Low | 1,550.17% | |
Range | -4.45 | |
Gap Up/Down | -2.05 |
Fundamentals | ||
Market Capitalization (Mln) | 538 | |
EBIDTA | -36,784,140 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 68.00 | |
Book Value | 9.2280 | |
Earnings Per Share | -10.3100 | |
EPS Estimate Current Quarter | -1.0900 | |
EPS Estimate Next Quarter | -1.2000 | |
EPS Estimate Current Year | -5.8600 | |
EPS Estimate Next Year | -5.8000 | |
Diluted EPS (TTM) | -10.3100 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | -0.2636 | |
Return on equity (TTM) | -0.5952 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | -1.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -16,136,826 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 1,490.7854 | |
Revenue Enterprise Value | 8.2564 | |
EBITDA Enterprise Value | -9.6587 | |
Shares | ||
Shares Outstanding | 10,507,200 | |
Shares Float | 6,776,432 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.08 | |
Insider (%) | 0.68 | |
Institutions (%) | 63.49 |
06/03 13:03 EST - seekingalpha.com
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
06/01 10:00 EST - globenewswire.com
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.
05/30 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.
05/23 17:05 EST - globenewswire.com
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
05/09 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.
05/07 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
05/01 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.
04/24 16:05 EST - globenewswire.com
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.
04/19 14:30 EST - investorplace.com
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
04/02 08:00 EST - globenewswire.com
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.
03/17 09:10 EST - 247wallst.com
Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
The Oracle of Omaha has once more bolstered his stake in a media giant's tracking stocks.
Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
The Oracle of Omaha has once more bolstered his stake in a media giant's tracking stocks.
03/15 09:51 EST - zacks.com
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
03/12 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
NORWOOD, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
NORWOOD, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.
03/08 20:02 EST - investorplace.com
All Three of Our Analysts Agree
Personalized health screening from a “smart toilet”
All Three of Our Analysts Agree
Personalized health screening from a “smart toilet”
03/06 08:00 EST - globenewswire.com
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.
02/28 08:00 EST - globenewswire.com
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
02/12 08:53 EST - 247wallst.com
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
Another Huge Buffett Purchase Highlights Recent Insider Buying
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
02/06 09:50 EST - globenewswire.com
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
02/05 12:09 EST - 247wallst.com
Insider Buying at These Biotechs Is Huge
As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.
Insider Buying at These Biotechs Is Huge
As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.
02/05 08:40 EST - marketbeat.com
Corbus Pharmaceuticals stock: An explosive 342% YTD surge
Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise of over 300% year-to-date. This is thanks to fresh news released two Fridays ago, on January 26.
Corbus Pharmaceuticals stock: An explosive 342% YTD surge
Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise of over 300% year-to-date. This is thanks to fresh news released two Fridays ago, on January 26.